File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Development and validation of the Osteoporosis Patient Satisfaction Questionnaire (OPSQ)

TitleDevelopment and validation of the Osteoporosis Patient Satisfaction Questionnaire (OPSQ)
Authors
Issue Date2010
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/maturitas
Citation
Maturitas, 2010, v. 65 n. 1, p. 55-63 How to Cite?
AbstractObjectives: To develop and validate the Osteoporosis Patient Satisfaction Questionnaire (OPSQ) and to assess the opinion of postmenopausal osteoporotic women towards pharmaceutical care. Methods: A 16-item instrument was designed. Each response consists of a five-point Likert-like scale with higher scores indicating greater satisfaction. The face and content validity was established via consultation with an endocrinologist and three pharmacists as well as feedback from participants in a preliminary study. Postmenopausal osteoporotic women taking bisphosphonates were recruited and randomly allocated to the intervention (n = 90) and control groups (n = 90). Pharmaceutical care was provided at month 2 to the intervention group while the control group received standard pharmacy services. The OPSQ was administered at month 6 (end of the intervention period), to assess patients' satisfaction. Factor analysis was performed using varimax rotation. Internal reliability was established using Cronbach's α. Construct validity was performed by using the Mann-Whitney U test. Results: The internal reliability of the OPSQ produced a Cronbach's α of 0.86. Factor analysis identified one component in the OPSQ, which measured patient satisfaction. The intervention group showed significantly better overall OPSQ score than the control group (91.89 ± 7.22% versus 84.32 ± 7.48%, p < 0.001). This indicates that the OPSQ was able to differentiate between participants who received pharmaceutical care from those who did not. Conclusions: The 16-item OPSQ developed in this study has high internal reliability and is a valid instrument for assessing osteoporotic women's satisfaction with pharmaceutical care service in Malaysia. © 2009 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/171391
ISSN
2015 Impact Factor: 3.12
2015 SCImago Journal Rankings: 1.107
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, PSMen_US
dc.contributor.authorChua, SSen_US
dc.contributor.authorChan, SPen_US
dc.contributor.authorLow, WYen_US
dc.contributor.authorWong, ICKen_US
dc.date.accessioned2012-10-30T06:13:49Z-
dc.date.available2012-10-30T06:13:49Z-
dc.date.issued2010en_US
dc.identifier.citationMaturitas, 2010, v. 65 n. 1, p. 55-63en_US
dc.identifier.issn0378-5122en_US
dc.identifier.urihttp://hdl.handle.net/10722/171391-
dc.description.abstractObjectives: To develop and validate the Osteoporosis Patient Satisfaction Questionnaire (OPSQ) and to assess the opinion of postmenopausal osteoporotic women towards pharmaceutical care. Methods: A 16-item instrument was designed. Each response consists of a five-point Likert-like scale with higher scores indicating greater satisfaction. The face and content validity was established via consultation with an endocrinologist and three pharmacists as well as feedback from participants in a preliminary study. Postmenopausal osteoporotic women taking bisphosphonates were recruited and randomly allocated to the intervention (n = 90) and control groups (n = 90). Pharmaceutical care was provided at month 2 to the intervention group while the control group received standard pharmacy services. The OPSQ was administered at month 6 (end of the intervention period), to assess patients' satisfaction. Factor analysis was performed using varimax rotation. Internal reliability was established using Cronbach's α. Construct validity was performed by using the Mann-Whitney U test. Results: The internal reliability of the OPSQ produced a Cronbach's α of 0.86. Factor analysis identified one component in the OPSQ, which measured patient satisfaction. The intervention group showed significantly better overall OPSQ score than the control group (91.89 ± 7.22% versus 84.32 ± 7.48%, p < 0.001). This indicates that the OPSQ was able to differentiate between participants who received pharmaceutical care from those who did not. Conclusions: The 16-item OPSQ developed in this study has high internal reliability and is a valid instrument for assessing osteoporotic women's satisfaction with pharmaceutical care service in Malaysia. © 2009 Elsevier Ireland Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/maturitasen_US
dc.relation.ispartofMaturitasen_US
dc.subject.meshAgeden_US
dc.subject.meshBone Density Conservation Agents - Administration & Dosageen_US
dc.subject.meshCohort Studiesen_US
dc.subject.meshCounseling - Methodsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMalaysiaen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOsteoporosis, Postmenopausal - Prevention & Control - Therapyen_US
dc.subject.meshOutcome Assessment (Health Care)en_US
dc.subject.meshPatient Education As Topic - Methodsen_US
dc.subject.meshPatient Satisfaction - Statistics & Numerical Dataen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshPsychometricsen_US
dc.subject.meshQuality Of Lifeen_US
dc.subject.meshQuestionnairesen_US
dc.subject.meshReproducibility Of Resultsen_US
dc.subject.meshWomen's Healthen_US
dc.titleDevelopment and validation of the Osteoporosis Patient Satisfaction Questionnaire (OPSQ)en_US
dc.typeArticleen_US
dc.identifier.emailWong, ICK:wongick@hku.hken_US
dc.identifier.authorityWong, ICK=rp01480en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.maturitas.2009.10.006en_US
dc.identifier.pmid19962839-
dc.identifier.scopuseid_2-s2.0-72149105591en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-72149105591&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume65en_US
dc.identifier.issue1en_US
dc.identifier.spage55en_US
dc.identifier.epage63en_US
dc.identifier.isiWOS:000273856900011-
dc.publisher.placeIrelanden_US
dc.identifier.scopusauthoridLai, PSM=35332387200en_US
dc.identifier.scopusauthoridChua, SS=9841352700en_US
dc.identifier.scopusauthoridChan, SP=7404255462en_US
dc.identifier.scopusauthoridLow, WY=27167730500en_US
dc.identifier.scopusauthoridWong, ICK=7102513915en_US
dc.identifier.citeulike6401028-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats